Comparison of risk of anaphylactic reactions between Exendin‐4 and human‐based GLP‐1 RAs versus Dipeptidyl Peptidase‐4 inhibitors in patients with Type 2 Diabetes Mellitus
Latest Information Update: 08 Dec 2020
At a glance
- Drugs Albiglutide (Primary) ; Dulaglutide (Primary) ; Exenatide (Primary) ; Liraglutide (Primary) ; Lixisenatide (Primary) ; Semaglutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- 08 Dec 2020 New trial record